Data suggest that chemotherapy is a sound treatment option for urothelial cancer across the disease spectrum. However, despite a twofold increase in survival in patients receiving chemotherapy, it does not seem to be offered to all patients.
This is a preview of subscription content, log in via an institution to check access.
References
Yagoda, A. Chemotherapy of urothelial tumors. Cancer 60 (Suppl. 3), 574–585 (1987).
Bamias, A. et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive/advanced cancer of the urothelium (RISC). Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdx692 (2017).
Sonpavde, G. et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin. Genitourin Cancer 10, 1–5 (2012).
Galsky, M. D. et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J. Clin. Oncol. 29, 2432–2438 (2011).
Moreales-Barrera, R. et al. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur. J. Cancer 48, 1816–1821 (2012).
Lane, B. R. et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for administration of perioperative chemotherapy. Cancer 116, 2967–2973 (2010).
Kaag, M. et al. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 114, 674–679 (2014).
Raman, J. D. et al. High rates of advanced disease, complications, and decline in renal function after radical nephroureterectomy. Urol. Oncol. 32, e9–e14 (2014).
Aziz, A. et al. Perioperative chemotherapy in upper tract urothelial carcinoma: a comphrehensive review. World J. Urol. 35, 1401–1407 (2017).
Porten, S. et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120, 1794–1799 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Raman, J. Optimizing and integrating cisplatin-based chemotherapy across the disease spectrum. Nat Rev Urol 15, 139–140 (2018). https://doi.org/10.1038/nrurol.2017.213
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.213
- Springer Nature Limited